Haemonetics Corp (HAE)
Industry Medical Devices
This stock can be held in an Investment ISA and an Investment Account
Sell
$47.00
Buy
$80.00
$0.09 (+0.11%)
Prices updated at 10 Jun 2026, 23:42 EDT
| Prices minimum 15 mins delay
Prices in USD
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company ope ...
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Medical Devices
Chairman
Ms. Ellen M. Zane
CEO
Mr. Christopher A. Simon
Most recent earnings
31 Mar 2026
Fiscal year end
31 Mar 2026
Employees
3,009
Head office
125 Summer Street
Boston
United States
02110
Key personnel
Owner name | Salary |
|---|---|
Mr. Charles J. Dockendorff Independent Director | 0.10m |
Ms. Ellen M. Zane Chairman of the Board | 0.25m |
Mr. Michael J. Coyle Independent Director | 0.09m |
Dr. Mark W. Kroll,PhD,F.A.C.C.,F.H.R.S. Independent Director | 0.09m |
Mr. Robert E. Abernathy Independent Director | 0.11m |
Ms. Diane M. Bryant Independent Director | 0.09m |
Dr. Claire Pomeroy, M.B.A.,M.D. Independent Director | 0.10m |
Mr. Christopher A. Simon Director, President and Chief Executive Officer | 1.10m |
Ms. Michelle L. Basil Executive Vice President and General Counsel | 0.56m |
Mr. Lloyd E. Johnson Independent Director | 0.11m |
Ms. Laurie A. Miller Senior Vice President and Chief Human Resources Officer | - |
Mr. James C. D’Arecca Executive Vice President and Chief Financial Officer | 0.60m |
Mr. Roy Galvin Executive Vice President and Chief Commercial Officer | 0.55m |
Ms. Maryanne E. Farris Vice President and Chief Accounting Officer | - |
Mr. Frank W. Chan Executive Vice President and Chief Operating Officer | 0.52m |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| BlackRock Inc | 5,619,979 |
| Vanguard Group Inc | 4,761,135 |
| Neuberger Berman Investment Advisers LLC | 3,560,918 |
| Neuberger Berman Group LLC | 3,560,918 |
| BlackRock Fund Advisors | 3,540,570 |
Director dealings
Date | Action |
|---|---|
| 10 Nov 2025 | - |
| 31 Oct 2025 | - |
| 17 Sep 2025 | - |
| 24 Jul 2025 | - |
| 24 Jul 2025 | - |
| 24 Jul 2025 | - |
| 24 Jul 2025 | - |
| 24 Jul 2025 | - |
| 24 Jul 2025 | - |
| 24 Jul 2025 | - |
| 24 Jul 2025 | - |
| 05 Jun 2025 | - |
| 05 Jun 2025 | - |
| 30 May 2025 | - |
| 30 May 2025 | - |
| 30 May 2025 | - |
| 30 May 2025 | - |
| 30 May 2025 | - |
| 30 May 2025 | - |
| 16 May 2025 | - |
Please note that past performance is not a reliable indicator of future returns.